Last reviewed · How we verify
Placebo for Rosuvastatin
Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.
Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Used for Hypercholesterolemia, Hyperlipidemia.
At a glance
| Generic name | Placebo for Rosuvastatin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | statin |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HMG-CoA reductase, rosuvastatin reduces the liver's production of low-density lipoprotein (LDL) cholesterol, also known as 'bad' cholesterol. This leads to an increase in high-density lipoprotein (HDL) cholesterol, or 'good' cholesterol, and a decrease in triglycerides. The net effect is a reduction in the risk of cardiovascular events such as heart attacks and strokes.
Approved indications
- Hypercholesterolemia
- Hyperlipidemia
Common side effects
- Muscle pain
- Liver enzyme elevation
- Diarrhea
Key clinical trials
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (PHASE3)
- A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (PHASE2, PHASE3)
- Investigation of the Gut Microbiome and Statin Response (PHASE4)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study (EARLY_PHASE1)
- Effect of Statins on Crohn's Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Rosuvastatin CI brief — competitive landscape report
- Placebo for Rosuvastatin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI